GYENNO Science announced that the company has received RMB 100m funding in Series B+ round, co-led by Eight Roads Ventures China and Qiming Venture Partners with participation from F-Prime Capital.
Founded in 2013 by a cross-disciplinary team, GYENNO Science has been laser-focused on delivering clinical & research value to CNS specialists & patients, starting with Parkinson’s Disease (PD).
The PD patients represent a sizable and rapidly growing population in China. By 2030, driven by the demographic shift, it is estimated that Chinese PD patients could reach 4.9 million, accounting for half of the world’s Parkinson’s Disease population. However, the supply of PD physicians is constrained, with around 300 quality specialists in China, mainly concentrated in major cities, to treat patients.
“Eight Roads closely follows neurodegenerative diseases like Parkinson’s Disease and is a long-time supporter of frontier scientific researches in this space,” said Cody Yin, Principal of Eight Roads, “GYENNO has gained wide recognition and support from the PD ecosystem and has partnered with leading academic centers, biopharma in China and globally. We are proud to partner with GYENNO to support its vision and further development.”